AngioDynamics (NASDAQ:ANGO) Hits New 1-Year High – Time to Buy?

AngioDynamics, Inc. (NASDAQ:ANGO) reached a new 52-week high on Wednesday . The stock traded as high as $13.50 and last traded at $13.5390, with a volume of 49563 shares changing hands. The stock had previously closed at $13.37.

Analysts Set New Price Targets

Several analysts recently commented on ANGO shares. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Friday, November 28th. Canaccord Genuity Group upped their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and an average price target of $19.33.

AngioDynamics Stock Up 1.0%

The firm has a market capitalization of $561.14 million, a PE ratio of -17.46 and a beta of 0.49. The firm has a 50-day moving average price of $11.94 and a 200 day moving average price of $10.55.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The business had revenue of $75.71 million for the quarter, compared to analysts’ expectations of $72.69 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. The business’s quarterly revenue was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Equities research analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO James C. Clemmer acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, October 9th. The stock was acquired at an average price of $11.15 per share, for a total transaction of $111,500.00. Following the purchase, the chief executive officer owned 882,529 shares of the company’s stock, valued at $9,840,198.35. This represents a 1.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Lawrence T. Weiss bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The shares were purchased at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the purchase, the senior vice president directly owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. This trade represents a 11.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 20,890 shares of company stock valued at $239,532. 6.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently modified their holdings of ANGO. State of Alaska Department of Revenue acquired a new position in shares of AngioDynamics during the third quarter worth $25,000. Washington Trust Advisors Inc. acquired a new stake in AngioDynamics during the 3rd quarter worth $27,000. State of Wyoming purchased a new stake in AngioDynamics in the second quarter valued at $31,000. Russell Investments Group Ltd. boosted its stake in AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 4,268 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.